Opinion|Videos|November 1, 2024
Healthcare Resource Utilization Impact of GPRC5D-Targeted Therapies
Panelists discuss how the use of GPRC5D-targeted therapies impacts healthcare resource utilization in the community setting, including potential changes in hospitalizations, outpatient visits, and supportive care needs.
Advertisement
Episodes in this series
- How does the use of GPRC5D-targeted therapies affect healthcare resource utilization, such as hospitalizations, outpatient visits, and supportive care requirements in the community setting?
Advertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.